Lupin receives tentative approval for Apixaban Tablets

Lupin has received tentative approval from USFDA to market Apixaban Tablets, 2.5 mg and 5 mg. The tablet is indicated to treat several ailments including reducing the risk of stroke and systemic embolism. Shares could be in focus in the next trading session.

Lupin’s Apixaban Tablets, 2.5 mg and 5mg is the generic version of Bristol-Myers Squibb Company’s Eliquis Tablets, 2.5 mg and 5 mg. The tablet is indicated to treat several ailments including reducing the risk of stroke and systemic embolism in nonvalvular atrial fibrillation,  prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), following hip or knee replacement surgery,  treatment of DVT and PE and also reducing the risk of recurrent DVT and PE.     

Lupin Limited is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs). The Company offers solutions in the anti-tuberculosis (anti-TB) and cephalosporins therapy areas, products in the cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastro-intestinal, anti-infectives and non-steroidal anti-inflammatory drug therapy areas. 

On Monday, the shares of Lupin opened at Rs.840 per share as against Friday’s close of Rs.839. The shares of the company closed at Rs 815.05, down by a whopping 2.96 per cent. The intraday high was Rs 840.50 and intraday low was Rs. 810.95 per share on the BSE. Its 52-week high was Rs. 986 and 52-week low was Rs. 723.55 per share on the BSE. The BSE Sensex closed at 34,959.72 level, down by 2 per cent.